196 related articles for article (PubMed ID: 34139789)
1. Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint.
Lee J; Lemons N; Lorenze A; Chowdhary TS; Zinn Z; Gayam S
J Gastroenterol Hepatol; 2021 Dec; 36(12):3278-3285. PubMed ID: 34139789
[TBL] [Abstract][Full Text] [Related]
2. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease.
Brenner EJ; Long MD
Curr Opin Gastroenterol; 2019 Jul; 35(4):330-336. PubMed ID: 31021924
[TBL] [Abstract][Full Text] [Related]
5. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
Lee J; Clarke K
Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
[TBL] [Abstract][Full Text] [Related]
7. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.
Zelinkova Z; Bultman E; Vogelaar L; Bouziane C; Kuipers EJ; van der Woude CJ
World J Gastroenterol; 2012 Dec; 18(47):6967-73. PubMed ID: 23322995
[TBL] [Abstract][Full Text] [Related]
8. Skin side effects of inflammatory bowel disease therapy.
Torres J; Buche S; Delaporte E; Colombel JF
Inflamm Bowel Dis; 2013 Apr; 19(5):1086-98. PubMed ID: 23474780
[TBL] [Abstract][Full Text] [Related]
9. Drugs for inflammatory bowel disease.
Med Lett Drugs Ther; 2018 Jul; 60(1550):107-114. PubMed ID: 30036352
[No Abstract] [Full Text] [Related]
10. Disease-related and drug-induced skin manifestations in inflammatory bowel disease.
Hindryckx P; Novak G; Costanzo A; Danese S
Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):203-214. PubMed ID: 28095714
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update.
Barnhill MS; Steinberg JM; Jennings JJ; Lewis JH
Curr Gastroenterol Rep; 2020 Jul; 22(9):47. PubMed ID: 32671616
[TBL] [Abstract][Full Text] [Related]
12. Use of thiopurines in inflammatory bowel disease.
Frei P; Biedermann L; Nielsen OH; Rogler G
World J Gastroenterol; 2013 Feb; 19(7):1040-8. PubMed ID: 23467510
[TBL] [Abstract][Full Text] [Related]
13. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
Melo FJ; Magina S
Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
Pijls PA; Gilissen LP
Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of IBD therapies.
Scribano ML
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S210-1. PubMed ID: 18816669
[No Abstract] [Full Text] [Related]
17. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases.
Solitano V; D'Amico F; Correale C; Peyrin-Biroulet L; Danese S
Br Med Bull; 2020 Dec; 136(1):107-117. PubMed ID: 33200781
[TBL] [Abstract][Full Text] [Related]
18. Conventional drug therapy for inflammatory bowel disease.
Bryant RV; Brain O; Travis SP
Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
[TBL] [Abstract][Full Text] [Related]
19. Table: safety of drugs for IBD in pregnancy.
Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
[No Abstract] [Full Text] [Related]
20. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
